Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting

References

• Kojouharova M, Wiersma S, Ivanova T, Filipova R, Ivanova R, Vladimirova N, Teoharov P, Andonov A, Kevorkian A, Stoilova Y, Bakalova S, Bogdanova V, Vazelov E, Mushekov V, Vatcheva R, Savova A, Hasurdjiev S, Tcherveniakova T, Anotonov K, Krivoshiev S, Kunchev A, Troyancheva M, Kurchatova A, Petrova G, Gatcheva N,Galev A, FitzSimons D. Burden and prevention of viral hepatitis in Bulgaria. Viral Hepatitis Prevention Board Meeting, 2011 Mar 24–25; Sofia, Bulgaria.
   Google Scholar
• Castillo de Febres O, Chacon de Petrola M, Casanova de Escalona L, Naveda O, Naveda M, Estopinan M, Bordones G, Zambrano B,Garcia A, Dumas R. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children. Vaccine. 1999;18(7–8):656–64.
   PubMed Web of Science ®Google Scholar
• Dagan R, Greenberg D, Goldenberg D, Goldenbertg-Gethman P, Vidor E, Briantais P, Pinsk V, Athias O, Dumas R. Safety and immunogenicity of new formulation of an inactivated hepatitis A vaccine. Vaccine. 1999;17(15–16):1919–1925.
   PubMed Web of Science ®Google Scholar
• Demicheli V, Carniglia E, Fucci S. The use of hepatitis A vaccination in Italy: an economic evaluation. Vaccine. 2003;21: 2250–2257.
   PubMed Web of Science ®Google Scholar
• Dimitrova M., Kamusheva M, Petrova G. Literature review of the protective efficacy, safety and pharmacoeconomic benefits of the vaccination against hepatitis A infections. Sci Pharmacol. 2013;2:7–12.
   Google Scholar
• Furesz J, Scheifele DW, Palkonayay L. Safety and effectiveness of the new inactivated hepatitis A virus vaccine. Can Med Assoc J. 1995;152(3):343–348.
   Web of Science ®Google Scholar
• Manova M, Savova A, Stoimenova A, Petrova G. Budget impact analysis of HCV therapy cost after boceprevir addition to standard therapeutic regime. Value Health. 2012;15(7):A333.
   Web of Science ®Google Scholar
• Savova A, Petrova G, Gotzeva A, Kurcatova A, Koguharova M. Economic analysis 20 years after the introduction of universal HBV immunisation in Bulgaria. Biotechnol Biotechnol Equipment. 2012;26(1):2811–2816.
   Web of Science ®Google Scholar
• Savova Tzenova A. Quality of life of patients with HBV infection – case study with SF-36. Viral Hepatitis Prevention Board Meeting; 2011 Mar 24–25; Sofia, Bulgaria.
   Google Scholar
• Tcherveniakova T, Antonov K, Savova A. Clinical aspects and treatment of hepatitis. Viral Hepat. 2011;1(20):14–15.
   Google Scholar
• WHO: Evidence based recommendation for use of hepatitis A vaccines in immunization services: background paper for SAGE discussions. Geneva 2011 [cited 2014 May]. Available from: http://www.who.int/immunization/sage/previous_november2011/en/
   Google Scholar
• WHO: WHO: Position Paper on hepatitis A vaccines. Weekly epidemiological record. 2008;83:1–16.
   Google Scholar
• André FE, D’Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine. 1992;10(Suppl. 1 ):S160–8
   Google Scholar
• CDCP: Prevention of hepatitis A through active or passive immunization: Recommendation of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report. 1999; 10(Suppl.1):S160–8
   Google Scholar
• Kane MA. Perspective on the control of hepatitis A vaccination. Vaccine. 1992–1999;10(1):S93–6.
   Google Scholar
• WHO. Public health control of hepatitis A: Memorandum memorandum from a WHO meeting Bulletin of the World Health Organization. Bull World Health Organ. 1995;73(1):15–20.
   Web of Science ®Google Scholar
• Vacchino MN. Incidence of Hepatitis A in Argentina after vaccination. J Viral Hepat. 2008;15 ( Suppl 2):47–50.
   PubMed Web of Science ®Google Scholar
• Vladimirova N. Cyclic outbreak in the dissemination of the viral hepatitis A infection in Bulgaria during 2010–2012 analysis of the epidemiological indicators. Sci Infectol/Parasitol. 2013;1:21–24.
   Google Scholar
• Anonychuk AM, Tricco AC, Bauch CT, Pham B, Gilca V, Duval B, John-Baptiste A, Woo G, Krahn M. Cost-effectiveness analyses of hepatitis A vaccine. A systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics. 208;26(1):17–32.
   Google Scholar
• Luyten J, Beutels P. Costing infectious disease outbreaks for economic evaluation: a review for hepatitis A. Pharmacoeconomics. 2009;27(5):379–389.
   PubMed Web of Science ®Google Scholar
• Luyten J, Van de Sande S, Schrijver K, Van Damme P, Beutels P. Cost-effectiveness of hepatitis A vaccination for adults in Belgium.Vaccine. 2012;30:6070–6080.
   PubMed Web of Science ®Google Scholar
• Postma MJ, Bos J.M, Beutels Ph, Schilthuis H, Van den Hoek JR. Pharmacoeconomic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine. 2004;22:1862–1867.
   PubMed Web of Science ®Google Scholar
• Rajan E, Shattock AG, Fielding JF. Cost-effective analysis of hepatitis A prevention in Ireland. Am J Gastroenterol. 2000;95(1):223–226.
   PubMed Web of Science ®Google Scholar
• Valenzuela MT, Jacobs RJ, Arteaga O, Navarrete MS, Meyerhoff AS, Innis BL. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 2005; 23(32):4110–4119.
   Google Scholar
• National Centre for Infection and Parasitic Diseases: Epidemiological bulletin [cited 2013 Oct]. Available from: http://www.ncipd.org/index.php?page=126.
   Google Scholar
• National Statistics Institute. Demographic characteristic [cited 2013 Oct] Available from: http://www.nsi.bg
   Google Scholar
• National Council on Prices and Reimbursement of Medicinal Products: Appendix 3 [cited 2013 Oct] Available from: http://www.ncpr.com
   Google Scholar
• NHIF: National framework contract [cited 2013 Oct] Available from: http://www.nhif.bg
   Google Scholar
• Savova A. Regulatory characteristics and utilization of herbal medicinal products [dissertation]. Sofia (Bulgaria): Medical University of Sofia, Faculty of Pharmacy; 2006.
   Google Scholar
• Rascati KL. Essentials of pharmacoeconomics. Philadelphia (PA): Lippincott Williams & Wilkins; 2009. p. 98
   Google Scholar
• WHO: Hepatitis A report of Department of Communicable Disease Surveillance and Response [cited 2013 Oct]. Available from: http://www.who.int/eme
   Google Scholar
• WHO. Position paper on hepatitis A vaccines. 2012;87:261–276.
   Google Scholar
• Ordinance 15 of Ministry of Health. State Gazette 2005 [cited 2013 Oct]. Available from: http://www.dv.parliament.bg
   Google Scholar